Embecta (Nasdaq:EMBC), the BD diabetes business spinoff, may take a few years to move into a growth phase, analysts say. BTIG analysts Marie Thibault and Sam Eiber wrote a report labeling Embecta as a “Neutral” option on the market. BD initially announced it would spin off its diabetes business in 2021, finally completing the move […]
Wall Street Beat
Second Sight Medical merges with Nano Precision Medical, rebrands as Vivani Medical
Second Sight Medical (Nasdaq:EYES) announced today that it completed its merger with Nano Precision Medical and rebranded. In February, the two companies entered into a definitive agreement under which Nano Precision Medical (NPM) would merge with a wholly-owned subsidiary of Second Sight in an all-stock transaction, with NPM as the surviving company under Second Sight’s […]
Embecta stock soars on first full-quarter results after BD spinoff
Embecta (Nasdaq: EMBC) today posted third-quarter results today for the first time as a BD (NYSE: BDX) spinoff, beating the consensus forecast on Wall Street. The Parsippany, New Jersey-based diabetes technology company reported profits of $62.4 million, or $1.08 per share, on sales of $291.1 million for the three months ended June 30. RELATED: How […]
Senseonics stock is up as it sticks by revenue guidance
Senseonics (NYSE:SENS) shares were up slightly today on second-quarter results that came up shy of the consensus forecast. The Germantown, Maryland-based continuous glucose monitoring technology developer yesterday evening posted profits of $103.9 million, or 22¢ per share, on sales of $3.7 million for the three months ended June 30, 2022, for a massive bottom-line gain […]
Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
Wells Fargo downgraded Tandem Diabetes Care (Nasdaq:TNDM) as competitors apply pressure to the automated insulin delivery technology developer. According to SeekingAlpha, analysts led by Larry Biegelsen moved Tandem from “Overweight” to “Underweight” due to bullish expectations on Wall Street as the company’s competition, including Insulet and Medtronic, come to the fore. The street responded in kind, with […]
Tandem sinks on Q2 misses, slashed sales guidance
Tandem Diabetes Care (Nasdaq:TNDM) shares took a bit hit after hours on second-quarter results that missed the consensus forecast. Shares of TNDM were down 7.2% at $64 per share after the market closed, which was when it released its quarterly results. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device […]
Dexcom stock dips on missed Q2 projections with broader G7 launch ‘in coming weeks’
Dexcom (Nasdaq:DXCM) shares took a hit after hours today on second-quarter results that came up shy of the consensus forecast. Shares of DXCM were down 7.2% at $80.69 after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 2.4%. The San […]
West Pharmaceutical stock ticks up on Street-beating Q2 despite lowered guidance
West Pharmaceutical Services (NYSE:WST) shares rose before hours on second-quarter results that came in ahead of the consensus forecast. The Exton, Pennsylvania–based company posted profits of $188.5 million, or $2.48 per share, on sales of $771.3 million for the three months ended June 30, 2022, for a 0.6% bottom-line gain on sales growth of 6.6%. […]
Senseonics announces equity grants to employees
Senseonics (NYSE:SENS) announced that it made equity grants to new employees under its 2019 inducement plan. Germantown, Maryland–based Senseonics, which develops the Eversense family continuous glucose monitoring (CGM) systems, including the latest-generation Eversense E3 180-day CGM, made the equity grants in accordance with the NYSE American Company Guide Section 711(a). On July 1, 2022, Senseoincs’ […]
Retractable Technologies declares dividends
Retractable Technologies (NYSE:RVP) announced that its board of directors declared dividends to holders of its convertible preferred stock. The dividends declared to holders of Retractable Technologies’ Series II Class B and Series III Class B convertible preferred stock totals amounts of $39,050 and $19,061.25, respectively. Dividends have accrued a $1 per share per annum and […]
